Since this result could be partially biased by an unbalanced distribution of low grade tumors (grade II-III and secondary) in the ANXA2 Very Low subgroup, we then analyzed the impact of ANXA2 IHC score only in GBM patients. This evidence concerns the gene ANXA2 and glioblastoma.